(ABT) Abbott Laboratories - Overview
Stock: Pharmaceuticals, Diagnostics, Nutrition, Devices
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.89% |
| Yield on Cost 5y | 2.11% |
| Yield CAGR 5y | 7.01% |
| Payout Consistency | 96.8% |
| Payout Ratio | 46.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.0% |
| Relative Tail Risk | -8.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.60 |
| Alpha | -21.30 |
| Character TTM | |
|---|---|
| Beta | 0.233 |
| Beta Downside | 0.382 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.95% |
| CAGR/Max DD | 0.12 |
Description: ABT Abbott Laboratories January 26, 2026
Abbott Laboratories (NYSE: ABT) is a diversified health-care company operating four core segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The firm markets a broad portfolio that includes generic drugs for gastrointestinal, metabolic, and cardiovascular conditions; a suite of laboratory and point-of-care diagnostics (e.g., immunoassays, molecular PCR platforms, rapid lateral-flow tests for SARS-CoV-2 and other pathogens); infant and adult nutrition formulas; and a range of cardiovascular, diabetes, and neuromodulation devices.
According to Abbott’s FY 2023 earnings release (released February 2024), the company generated $43.1 billion in revenue, posted diluted earnings per share of $3.20, and returned a 4.2 % dividend yield. Free cash flow was $5.6 billion, supporting a 2024 capital-expenditure plan of roughly $3.5 billion, of which $1.2 billion is earmarked for expanding the diagnostics pipeline. R&D spending reached $4.0 billion, reflecting a continued focus on high-margin specialty drugs and next-generation point-of-care platforms.
Key macro drivers for Abbott’s segments include: (1) an aging U.S. and global population that raises demand for chronic-disease therapeutics and cardiac devices; (2) sustained post-pandemic emphasis on rapid, decentralized diagnostics, which is expanding the addressable market for Abbott’s molecular and point-of-care test kits; and (3) inflation-adjusted health-care spending growth of ~4 % YoY, which underpins revenue expansion in both the pharmaceutical and nutrition businesses. These drivers are offset by regulatory uncertainty in the U.S. drug pricing environment and potential supply-chain constraints for specialty ingredients.
For a deeper quantitative assessment, see the ValueRay analysis of ABT.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 6.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.25 > 1.0 |
| NWC/Revenue: 23.14% < 20% (prev 22.64%; Δ 0.50% < -1%) |
| CFO/TA 0.11 > 3% & CFO 9.12b > Net Income 6.52b |
| Net Debt (12.94b) to EBITDA (11.33b): 1.14 < 3 |
| Current Ratio: 1.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.75b) vs 12m ago 0.06% < -2% |
| Gross Margin: 55.51% > 18% (prev 0.51%; Δ 5500 % > 0.5%) |
| Asset Turnover: 53.54% > 50% (prev 51.53%; Δ 2.01% > 0%) |
| Interest Coverage Ratio: 25.18 > 6 (EBITDA TTM 11.33b / Interest Expense TTM 341.0m) |
Altman Z'' 3.40
| A: 0.12 (Total Current Assets 24.84b - Total Current Liabilities 14.58b) / Total Assets 84.18b |
| B: 0.58 (Retained Earnings 49.10b / Total Assets 84.18b) |
| C: 0.10 (EBIT TTM 8.59b / Avg Total Assets 82.80b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 32.92b) |
| Altman-Z'' Score: 3.40 = A |
What is the price of ABT shares?
Over the past week, the price has changed by +1.40%, over one month by -12.83%, over three months by -10.85% and over the past year by -11.94%.
Is ABT a buy, sell or hold?
- StrongBuy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 133.1 | 20.1% |
| Analysts Target Price | 133.1 | 20.1% |
| ValueRay Target Price | 105.6 | -4.8% |
ABT Fundamental Data Overview February 07, 2026
P/E Forward = 19.0476
P/S = 4.2828
P/B = 3.6925
P/EG = 4.1675
Revenue TTM = 44.33b USD
EBIT TTM = 8.59b USD
EBITDA TTM = 11.33b USD
Long Term Debt = 11.60b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.34b USD (from shortTermDebt, two quarters ago)
Debt = 12.94b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 12.94b USD (using Total Debt 12.94b, CCE unavailable)
Enterprise Value = 202.79b USD (189.85b + Debt 12.94b - (null CCE))
Interest Coverage Ratio = 25.18 (Ebit TTM 8.59b / Interest Expense TTM 341.0m)
EV/FCF = 29.32x (Enterprise Value 202.79b / FCF TTM 6.92b)
FCF Yield = 3.41% (FCF TTM 6.92b / Enterprise Value 202.79b)
FCF Margin = 15.60% (FCF TTM 6.92b / Revenue TTM 44.33b)
Net Margin = 14.72% (Net Income TTM 6.52b / Revenue TTM 44.33b)
Gross Margin = 55.51% ((Revenue TTM 44.33b - Cost of Revenue TTM 19.72b) / Revenue TTM)
Gross Margin QoQ = 57.05% (prev 55.75%)
Tobins Q-Ratio = 2.41 (Enterprise Value 202.79b / Total Assets 84.18b)
Interest Expense / Debt = 0.32% (Interest Expense 42.0m / Debt 12.94b)
Taxrate = 24.68% (582.0m / 2.36b)
NOPAT = 6.47b (EBIT 8.59b * (1 - 24.68%))
Current Ratio = 1.70 (Total Current Assets 24.84b / Total Current Liabilities 14.58b)
Debt / Equity = 0.25 (Debt 12.94b / totalStockholderEquity, two quarters ago 50.95b)
Debt / EBITDA = 1.14 (Net Debt 12.94b / EBITDA 11.33b)
Debt / FCF = 1.87 (Net Debt 12.94b / FCF TTM 6.92b)
Total Stockholder Equity = 49.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.88% (Net Income 6.52b / Total Assets 84.18b)
RoE = 13.18% (Net Income TTM 6.52b / Total Stockholder Equity 49.50b)
RoCE = 14.05% (EBIT 8.59b / Capital Employed (Equity 49.50b + L.T.Debt 11.60b))
RoIC = 10.21% (NOPAT 6.47b / Invested Capital 63.32b)
WACC = 6.36% (E(189.85b)/V(202.79b) * Re(6.78%) + D(12.94b)/V(202.79b) * Rd(0.32%) * (1-Tc(0.25)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.03%
[DCF Debug] Terminal Value 84.16% ; FCFF base≈6.74b ; Y1≈6.59b ; Y5≈6.65b
Fair Price DCF = 91.74 (EV 172.46b - Net Debt 12.94b = Equity 159.52b / Shares 1.74b; r=6.36% [WACC]; 5y FCF grow -3.37% → 2.90% )
EPS Correlation: 1.61 | EPS CAGR: -3.73% | SUE: 0.63 | # QB: 0
Revenue Correlation: 20.64 | Revenue CAGR: -0.99% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.15 | Chg30d=-0.051 | Revisions Net=-16 | Analysts=23
EPS current Year (2026-12-31): EPS=5.68 | Chg30d=+0.001 | Revisions Net=+4 | Growth EPS=+10.2% | Growth Revenue=+8.1%
EPS next Year (2027-12-31): EPS=6.24 | Chg30d=-0.005 | Revisions Net=+1 | Growth EPS=+9.9% | Growth Revenue=+7.5%